Leafly Holdings, Inc. /DE reported the three months ended March 31, 2024 results: revenue $9.0 million, net income $2.4 million.
“Delivered Q1 2024 revenue of $9.0 million Reported net loss of $2.4 million”
Earnings Releases
Quarterly and annual results disclosed under 8-K Item 2.02.
89bio, Inc. reported the first quarter ended March 31, 2024 results: net income $51.7 million.
“89bio reported a net loss of $51.7 million for the three months ended March 31, 2024”
UWM Holdings Corp reported first quarter ended March 31, 2024 results: revenue $27.6 billion, net income $180.5 million, EPS $0.09.
“--- EARNINGS RELEASE Document Exhibit 99.1 UWM Holdings Corporation Announces First Quarter 2024 Results First Quarter Net Income of $180.5 Million. Loan Origination Volume of $27.6 Billion, Including Purchase Volume of $22.1 Billion. PONTIAC, M I, May 9, 2024 - UWM Holdings Corporation (NYSE: UWMC) (the "Company"), the publicly traded indirect parent of United”
Phathom Pharmaceuticals, Inc. reported the first quarter of 2024 results: revenue Net revenues for the first quarter 2024 were $1.9 million, net income Net loss for the first quarter 2024 was $82.9 million.
“Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024”
Morgan Stanley Direct Lending Fund reported first quarter ended March 31, 2024 results: EPS $0.59.
“On May 9, 2024, Morgan Stanley Direct Lending Fund (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
TerrAscend Corp. reported first quarter ended March 31, 2024 results: revenue Net Revenue was $80.6 million.
“except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 TerrAscend Reports First Quarter 2024 Financial Results Net Revenue of $80.6 million, an increase of 16.1% year-over-year Cash Flow from operations of $13.3 million and Free Cash Flow 1 of $10.5 million in the quarter TORONTO, May 9, 2024 - TerrAscend Corp.”
Cerence Inc. reported Second quarter fiscal year 2024 ended March 31, 2024 results: revenue $67.8 million, net income GAAP net loss of $(278.0) million, EPS $(6.66) GAAP net loss per share - diluted. Guidance lowered.
“Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today reported its second quarter fiscal year 2024 results for the quarter ended March 31, 2024.”
AvePoint, Inc. reported first quarter ended March 31, 2024 results: revenue $74.5 million. Guidance raised.
“99.1 AvePoint Announces First Quarter 2024 Financial Results First quarter SaaS revenue of $51.3 million, representing 44% year-over-year growth First quarter Total revenue of $74.5 million, representing 25% year-over-year growth Total ARR of $274.5 million, representing 23% year-over-year growth JERSEY CITY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- AvePoint (NASDAQ:”
Advantage Solutions Inc. updated its first quarter ended March 31, 2024 guidance (reaffirmed).
“today reported financial results for its first quarter ended March 31, 2024.”
Endeavor Group Holdings, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 9, 2024, Endeavor Group Holdings, Inc. announced its financial results for the quarter ended March 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.”
Lantern Pharma Inc. reported financial results for the first quarter 2024.
“On May 9, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2024.”
HOOKIPA Pharma Inc. reported first quarter ended March 31, 2024 results: revenue $36.6 million.
“Revenue was $36.6 million for the three months ended March 31, 2024, compared to $3.2 million for the same period in 2023.”
Privia Health Group, Inc. reported the first quarter ended March 31, 2024 results: revenue $ 415.2, net income $ 3.0, EPS $ 0.03. Guidance reaffirmed.
“Privia Health Reports First Quarter 2024 Financial Results – Practice Collections +7.4% compared to 1Q’23 – Implemented Providers +17.3% compared to 1Q’23 – Company Reiterated Full Year 2024 Guidance ARLINGTON, VA – May 9, 2024 – Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the first quarter ended March 31, 2024. For the Three Months Ended March 31, ($ in millions, except per share amounts) 2024 2023 Change (%) Total revenue $ 415.2 $ 386.3 7.5 % Gross profit $ 93.4 $ 83.0 12.5 % Operating income $ 0.8 $ 6.7 (87.7) % Net income a $ 3.0 $ 7.3 (59.3) % Non-GAAP adjusted net income b $ 22.5 $ 19.3 16.6 % Net income per share $ 0.03 $ 0.06 (50.0) % Non-GAAP adjusted net income per share $ 0.18 $ 0.16 12.5 %”
Microvast Holdings, Inc. reported the period ended March 31, 2024 results: revenue $81.4 million, net income Net loss of $24.8 million, EPS Net loss per share of $0.08. Guidance initiated.
“Chief Financial Officer --- EX-99.1 (EX-99.1) --- Microvast Reports First Quarter 2024 Financial Results • Record company Q1 revenue, increased 73.2% year over year to $81.4 million • Gross margin increased from 10.3% to 21.2%, a 10.9 percentage point improvement year over year STAFFORD, Texas, USA, May 9, 2024 — Microvast Holdings, Inc. (NASDAQ: MVST)”
Karat Packaging Inc. reported 2024 first quarter ended March 31, 2024 results: revenue $95.6 million, net income $6.5 million, EPS $0.31 per diluted share. Guidance initiated.
“foodservice products and related items, today announced financial results for its 2024 first quarter ended March 31, 2024. First Quarter 2024 Highlights • Net sales of $95.6 million, versus $95.8 million in the prior-year quarter. • Gross profit of $37.6 million, versus $38.1 million in the prior-year quarter. • Gross margin of 39.3 percent versus 39.8”
Desktop Metal, Inc. reported first quarter of fiscal year 2024 results: revenue $40.6 million, net income $(52.1) million. Guidance reaffirmed.
“Revenue of $40.6 million, down less than 2% year over year”
Trulieve Cannabis Corp. reported the quarter ended March 31, 2024 results: revenue $298 million, net income net loss of $23 million.
“--- tcnnf-2024xq1xexx991 Exhibit 99.1 Trulieve Reports First Quarter 2024 Results Demonstrating Core Business Strength and Cash Generation • First quarter performance of $298 million in revenue, up 4% sequentially, and 58% gross margin • Strong cash flow from operations of $139 million and free cash flow of $124 million* in Q1 2024 • Definitive progress made”
Whole Earth Brands, Inc. reported first quarter ended March 31, 2024 results: revenue $129.5 million, net income $9.4 million.
“FIRST QUARTER 2024 RESULTS · Consolidated product revenues were $129.5 million, a decrease of 2.2% on a reported basis and 2.3% on a constant currency basis, as compared to the prior year first quarter. · Reported gross profit was $37.3 million, compared to $32.3 million in the prior year first quarter. The increase was largely driven by lower raw material and freight costs, a decline in costs associated with the supply chain reinvention project, and favorable product mix. Adjusted gross profit was $42.1 million, compared to $39.5 million in the prior year first quarter. · Reported gross profit margin increased to 28.8% in the first quarter of 2024, compared to 24.4% in the prior year period. Adjusted gross profit margin increased to 32.5%, compared to 29.9% in the prior year first quarter. · Consolidated operating income was $3.1 million compared to $3.0 million in the prior year first quarter. The increase was driven by the improvement in gross margin, which was partially offset by c”
Fathom Holdings Inc. reported the first quarter ended March 31, 2024 results: revenue $70.5 million, net income $5.9 million, or $0.31 per share, EPS $0.31 per share.
“transactions decreased primarily due to continuation of high interest rates in the first quarter of 2024. Fathom’s total revenue decreased 9.0% for the 2024 first quarter to $70.5 million, from $77.5 million for the 2023 first quarter. The decrease in total revenue was comprised of a 10.6% decrease in brokerage revenue largely attributable to the decline in”
Equillium, Inc. reported the first quarter ended March 31, 2024 results: revenue $10.7 million, net income $2.7 million, EPS $(0.08) per basic and diluted share.
“1 Option exercise payment is denominated in Japanese yen (5 billion) and subject to currency exchange rates at the time of payment. Revenue for the first quarter of 2024 was $10.7 million, compared to $8.9 million during the same period in 2023. Revenue in the first quarters of 2024 and 2023 consisted entirely of itolizumab development funding and amortization of”
Kronos Bio, Inc. reported the quarter ended March 31, 2024 results: net income $30.0 million, or $0.50 per share, EPS $0.50 per share.
“Net loss for the first quarter of 2024 was $30.0 million, or $0.50 per share, including non-cash stock-based compensation expense of $7.7 million.”
Inhibrx, Inc. reported the first quarter of 2024 results: net income $78.7 million, EPS $1.44 per share.
“Net loss was $78.7 million during the first quarter of 2024, or $1.44 per share, compared to $48.9 million during the first quarter of 2023, or $1.12 per share.”
Rallybio Corp reported financial results for the quarter ended March 31, 2024.
“On May 9, 2024, Rallybio Corporation issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Cambium Networks Corp reported first quarter 2024 ended March 31, 2024 results: revenue $42.3 million, net income $26.4 million or a loss of $0.95 per diluted share, EPS $0.95 per diluted share. Guidance reaffirmed.
“Cambium Networks Reports First Quarter 2024 Financial Results • Revenues of $42.3 million”
Nuveen Churchill Direct Lending Corp. reported first quarter ended March 31, 2024 results: revenue $51.6 million, EPS $0.57 per share.
“there were no loans on non-accrual. RESULTS OF OPERATIONS Investment Income Investment income, primarily attributable to interest and fees on our debt investments, increased to $51.6 million for the three months ended March 31, 2024, from $34.0 million for the three months ended March 31, 2023, primarily due to an increase in interest income from higher weighted”
Arlo Technologies, Inc. reported first quarter ended March 31, 2024 results: revenue $124.2 million, EPS $(0.10). Guidance initiated.
“• Q1 total revenue of $124.2 million, an increase of 11.9% year over year. • Record Q1 service revenue of $56.7 million, growing 29.0% year over year. • Q1 GAAP services gross margin of 76.0% and non-GAAP services gross margin of 76.7%. • GAAP gross profit of $47.4 million, an increase of 34.5% year over year; non-GAAP gross profit of $48.9 million, an increase of 35.0% year over year. • GAAP gross margin of 38.1%; non-GAAP gross margin of 39.4%. • GAAP net loss per share of $(0.10); non-GAAP earnings per share of $0.09.”
MeiraGTx Holdings plc reported financial results for the first quarter ended March 31, 2024.
“On May 9, 2024, MeiraGTx Holdings plc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Piedmont Lithium Inc. reported quarter ended March 31, 2024 results: revenue $13.4 million, net income ($23.6 million), EPS ($1.22) per diluted share.
“Revenue of $13.4 million on sales of approximately 15,500 dmt of spodumene concentrate • $71.4 million in cash as of March 31, 2024; working capital nearly doubled from 2023 year end • 2024 outlook for shipments to more than double and investments to decrease more than 50% in H2’24 vs. H1’24”
BioXcel Therapeutics, Inc. reported first quarter of 2024 results: revenue $582,000, net income $26.8 million.
“of BXCL701 and KEYTRUDA® (pembrolizumab) in metastatic pancreatic ductal adenocarcinoma (PDAC). First Quarter 2024 Financial Results Net Revenue: Net revenue from IGALMI was $582,000 for the first quarter of 2024, compared to $206,000 for the same period in 2023, representing a 182% increase. Sequential quarterly revenue increased 55% in Q1 2024 from the”
Repay Holdings Corp updated its first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 9, 2024, Repay Holdings Corporation (the “Company”) issued a press release announcing the results of the Company’s operations for the quarter ended March 31, 2024.”
IBEX Ltd reported third fiscal quarter ended March 31, 2024 results: revenue $126.8 million, net income $10.3 million, EPS $0.57.
“emerging Technology companies this quarter, totaling fifteen for the year-to-date compared to eight in the prior year-to-date period. GAAP Financials: • Third quarter revenue of $126.8 million declined 3.6% from the prior year quarter. • Net income of $10.3 million compared to $11.3 million in the prior year quarter. Net income margin decreased to 8.1% from 8.6% in the”
Funko, Inc. reported 2024 full year results: revenue $1.047 billion to $1.103 billion. Guidance reaffirmed.
“Based on its current outlook, the company reiterated its 2024 full-year outlook and provided guidance for its 2024 second quarter, as follows: Current Outlook 2024 Full Year Net Sales $1.047 billion to $1.103 billion Adjusted EBITDA* $65 million to $85 million”
Funko, Inc. reported first quarter ended March 31, 2024 results: net income $23.7 million, EPS $0.45 per share.
“Net sales were $215.7 million compared with $251.9 million”
Eton Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: revenue $8.0 million, net income Net loss for the first quarter of 2024 was $0.8 million, EPS $0.03 per basic and diluted share.
“Net revenues for the first quarter of 2024 were $8.0 million compared with $5.3 million in the prior year period, an increase of 50%.”
Evergy, Inc. reported first quarter ended March 31, 2024 results: net income $122.7 million, EPS $0.53 per share. Guidance reaffirmed.
“today announced first quarter 2024 GAAP earnings of $122.7 million, or $0.53 per share”
Edgewise Therapeutics, Inc. reported financial results for first quarter of 2024.
“On May 9, 2024, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
ELUTIA INC. reported first quarter ended March 31, 2024 results: revenue $6.7 million, net income $18.0 million.
“second half of this year. First Quarter 2024 Financial Results For the three-month period ended March 31, 2024, as compared to the same period of 2023: · Overall net sales were $6.7 million, an increase of 5%. · Net sales of SimpliDerm were $3.6 million, compared to $2.3 million, an increase of 55%, as customer awareness and acceptance accelerated within the $1.6”
Cibus, Inc. reported financial results for the quarter ended March 31, 2024.
“Cibus, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2024.”
Black Diamond Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $18.2 million.
“Net loss for the first quarter of 2024 was $18.2 million”
Azitra, Inc. reported the quarter ended March 31, 2024 results: revenue $0, net income $2.9 million.
“Financial Results for the Year Ended December 31, 2023 ● Service Revenue – Related Party : The Company generated $0 service revenue during the quarter ended March 31, 2024, compared to $113,300 for the comparable period in 2023. ● Research and Development (R&D) expenses : R&D expenses for the quarter ended March 31, 2024, were $1.5 million compared to $0.8 million for the comparable period in 2023. ● General and Administrative (G&A) expenses : G&A expenses for the quarter ended March 31, 2024, were $1.5 million compared to $0.8 million for the comparable period in 2023. ● Net Loss was $2.9 million for the quarter ended March 31, 2024, compared to $2.5 million for the comparable period in 2023. ● Cash and cash equivalents : As of March 31, 2024, the Company had cash and cash equivalents of $3.0 million.”
PMV Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $15.3 million.
“PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
Applied Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $146.5 million, net income $83.9 million, EPS $0.67 per basic and diluted common share.
“full study results were published in the Journal of the American College of Cardiology (JACC). Financial Results · Cash and cash equivalents and short-term investments totaled $146.5 million as of March 31, 2024, compared with $49.9 million at December 31, 2023. · Research and development expenses for the three months ended March 31, 2024, were $12.2 million,”
Kinetik Holdings Inc. reported the quarter ended March 31, 2024 results: net income $35.4 million.
“On May 8, 2024, Kinetik Holdings Inc. issued a press release announcing financial and operating results for the fiscal quarter ended March 31, 2024.”
Co-Diagnostics, Inc. reported quarter ended March 31, 2024 results: revenue $0.5 million, net income Net loss of $9.3 million, EPS loss of $0.31 per fully diluted share.
“Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results SALT LAKE CITY, May 9, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Dx,” or the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: ● Revenue of $0.5 million, down from $0.6 million during the prior year. Grant revenue totaled $0.2 million while product revenue totaled $0.3 million ● Operating expenses of $10.5 million increased by 4.4% from the prior year due to an increase in research and development costs incurred for the development of tests currently in our pipeline ● Operating loss of $10.3 million compared to operating loss of $10.0 million in Q1 2023 ● Net loss of $9.3 million, compared to net loss of $5.8 million in the prior year, representing a loss of $0.31 per fully diluted share, compared to a loss of $0.20 per fully dilut”
Dianthus Therapeutics, Inc. /DE/ reported the quarter ended March 31, 2024 results: net income $13.7 million, EPS $0.54 net loss per share (basic and diluted).
“Net loss for the quarter ended March 31, 2024 was $13.7 million or $0.54 net loss per share (basic and diluted)”
Cars.com Inc. reported the first quarter ended March 31, 2024 results: revenue $180.2 million, net income $0.8 million, or $0.01 per diluted share. Guidance reaffirmed.
“technology company empowering the automotive industry, today released its financial results for the first quarter ended March 31, 2024. Q1 2024 Financial Highlights • Revenue of $180.2 million, up $13.1 million, or 8% year-over-year • Net income of $0.8 million, or $0.01 per diluted share, compared to Net income of $11.5 million, or $0.17 per diluted share, in the”
Zomedica Corp. reported full year 2024 results: revenue $31 to $35 million. Guidance reaffirmed.
“For the full year 2024, the Company continues to expect full year revenue in the range of $31 to $35 million, an increase of approximately 39% at the high end of the range, over full year 2023 revenue of $25.2 million.”
Zomedica Corp. reported the quarter ended March 31, 2024 results: revenue $6.3 million, net income $9.2 million, EPS $0.01 per share.
“Revenue for the three months ended March 31, 2024, was $6.3 million, compared to $5.5 million for the three months ended March 31, 2023, an increase of $0.8 million or approximately 14%. The increase was driven by growth in both operating segments: Therapeutic Devices and Diagnostics. Cost of revenue was $2.1 million, compared to $1.6 million for the three months ended March 31, 2023, an increase of $0.5 million. Margins remained strong at 66%, in line with expectations. Adjusting for our Qorvo Biotechnologies LLC (“QBT”) acquisition and other one-time items brings our gross margin for the quarter to over 69%, in line with recent levels. Operating expenses were $14.5 million, compared to $11.3 million for the three months ended March 31, 2023, an increase of $3.2 million or 28%. When adjusted for one-time, non-recurring charges, and expenses associated with ongoing QBT operations, total operating expenses grew just over 20% on a comparative basis. We continue to expect total operating”
INNOVATIVE INDUSTRIAL PROPERTIES INC reported the first quarter ended March 31, 2024 results: revenue $75.5 million, net income $39.1 million, EPS $1.36 per share.
“Generated total revenues of $75.5 million and net income attributable to common stockholders of $39.1 million, or $1.36 per share”
NI Holdings, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 9, 2024, the Company issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.